1. Home
  2. RUN vs COAG Comparison

RUN vs COAG Comparison

Compare RUN & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrun Inc.

RUN

Sunrun Inc.

SELL

Current Price

$7.81

Market Cap

2.1B

Sector

Miscellaneous

ML Signal

SELL

COAG

Hemab Therapeutics Holdings Inc. Common Stock

SELL

Current Price

$38.70

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RUN
COAG
Founded
2007
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
RUN
COAG
Price
$7.81
$38.70
Analyst Decision
Buy
Strong Buy
Analyst Count
19
7
Target Price
$13.59
★ $63.00
AVG Volume (30 Days)
★ 10.8M
468.0K
Earning Date
11-04-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 113.35
N/A
EPS
★ 1.60
N/A
Revenue
★ $858,578,000.00
N/A
Revenue This Year
$19.80
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.83
★ N/A
Revenue Growth
★ 12.97
N/A
52 Week Low
$6.78
$27.38
52 Week High
$21.95
$55.42

Technical Indicators

Market Signals
Indicator
RUN
COAG
Relative Strength Index (RSI) 44.28 48.31
Support Level $6.94 $28.46
Resistance Level $7.86 $38.87
Average True Range (ATR) 0.69 4.00
MACD -0.06 -0.46
Stochastic Oscillator 16.40 21.75

Price Performance

Historical Comparison
RUN
COAG

About RUN Sunrun Inc.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: